Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Request metadata listed "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc., trading as BASi).
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2009
Business Overview: The Company provides contract drug development services and research equipment to pharmaceutical, medical research, and biotechnology companies. Operations are divided into two segments: Contract Research Services (bioanalytical testing, toxicology, pharmacology) and Research Products (in vivo sampling systems, analytical instruments). The Company operates facilities in Indiana, Oregon, and the United Kingdom.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Total Revenue | $31.8 million | $41.7 million |
| Gross Profit | $7.6 million (23.9% margin) | $15.3 million (36.8% margin) |
| Operating Loss | $(4.6) million | $2.8 million income |
| Net Loss (Continuing Ops) | $(5.5) million | $0.5 million income |
| Cash from Operations | $2.0 million | $4.0 million |
| Cash & Equivalents (End of Period) | $0.9 million | $0.3 million |
| Total Debt (Long-term + Current) | $8.7 million | $9.2 million |
| Revolving Credit Outstanding | $1.8 million | $2.0 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 24% year-over-year, driven by a 26.6% drop in Services revenue and a 13.1% drop in Products revenue. This was attributed to the global economic recession, reduced R&D spending by clients, and project delays/cancellations.
- Margin Compression: Gross margin fell from 36.8% to 23.9%. The Services segment cost of revenue increased as a percentage of revenue (from 69.7% to 86.8%) due to high fixed costs amidst lower sales volume.
- Profitability Shift: The Company moved from an operating income of $2.8 million in 2008 to an operating loss of $4.6 million in 2009. This included a $0.5 million goodwill impairment charge related to the UK reporting unit.
- Discontinued Operations: The Company sold its Baltimore Clinical Pharmacology Research Unit (CPRU) in June 2008. Fiscal 2009 results reflect only continuing operations, whereas 2008 included a net loss of $2.0 million from discontinued operations.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects slow but continued improvement in new bookings for fiscal 2010. They anticipate improved gross margins due to cost controls implemented in late 2009. Revenue is projected to increase slightly in the second half of fiscal 2009 compared to the first half, a trend expected to continue.
- Liquidity and Debt Covenants: The Company faces significant liquidity risks. Substantially all assets are encumbered as security for debt. The Company has experienced covenant violations regarding fixed charge coverage ratios. While waivers and amendments were obtained from lenders (Regions Bank and National City/PNC) through early 2010, future compliance is uncertain. A new $3.0 million revolving line of credit was secured with Entrepreneur Growth Capital LLC in January 2010.
- Key Risks:
- Customer Concentration: Pfizer Inc. accounted for 7.0% of total revenue in 2009. Contracts are generally terminable on 30 days' notice.
- Market Conditions: Continued economic downturn and reduced R&D budgets by pharmaceutical clients pose a threat to future revenue.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting related to income tax accounting due to insufficient technical knowledge among staff.
- Contingencies: The Company remains contingently liable for $0.8 million annually through 2015 regarding the lease of the sold CPRU facility if the buyer fails to meet obligations.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the status of the fixed charge coverage ratio and tangible net worth covenants with Regions Bank and the new EGC credit facility, as the Company has a history of requiring waivers.
- Revenue Recovery: Monitor quarterly new order authorizations and backlog to confirm the projected rebound in the second half of fiscal 2009 and into fiscal 2010.
- Internal Control Remediation: Review subsequent filings to ensure the material weakness regarding income tax accounting has been remediated.
- Customer Concentration: Assess the stability of the relationship with Pfizer (7% of revenue) and the impact of potential contract terminations.
- Goodwill Impairment: Monitor the UK reporting unit's performance, as it already triggered a full goodwill impairment in 2009; further declines could impact other reporting units.